The intratumoral injection of STING agonists has shown great promise in preclinical cancer models and leads to an enhanced content of the tumor-intrinsic type I IFNs, increased C-X-C motif chemokine receptor 3–dependent (CXCR3-dependent) antitumor immunity, and increased survival (8). This evidence concerns the gene STING1 and cancer.